These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 7979841)

  • 1. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
    Insull W; Black D; Dujovne C; Hosking JD; Hunninghake D; Keilson L; Knopp R; McKenney J; Stein E; Troendle AJ
    Arch Intern Med; 1994 Nov; 154(21):2449-55. PubMed ID: 7979841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elderly patients with hypercholesterolaemia: a double-blind study of the efficacy, safety and tolerability of fluvastatin.
    Lye M; Valacio R; Reckless JP; Ghosh AK; Findlay IN; Ghosh MK; Passmore AP; Fulcher RA
    Coron Artery Dis; 1998; 9(9):583-90. PubMed ID: 9861520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
    Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K
    Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials.
    Winkler K; Ablethauser CB; Gimpelewicz C; Bortolini M; Isaacsohn JL
    Clin Ther; 2007 Sep; 29(9):1987-2000. PubMed ID: 18035198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide.
    Romano M; Mezzetti A; Marulli C; Ciabattoni G; Febo F; Di Ienno S; Roccaforte S; Vigneri S; Nubile G; Milani M; Davì G
    J Investig Med; 2000 May; 48(3):183-9. PubMed ID: 10822898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fluvastatin on plasma apolipoprotein-B-containing particles, including lipoprotein(a). European Fluvastatin Study Group.
    Dallongeville J; Fruchart JC; Pfister P; Bard JM
    J Intern Med Suppl; 1994; 736():95-101. PubMed ID: 7986315
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin Multicenter Study Group II.
    Arch Intern Med; 1993 Jun; 153(11):1321-9. PubMed ID: 8507122
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation: results of a randomised double blind placebo controlled study.
    O'Rourke B; Barbir M; Mitchell AG; Yacoub MH; Banner NR
    Int J Cardiol; 2004 Apr; 94(2-3):235-40. PubMed ID: 15093987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of fluvastatin 40 mg every other day versus 20 mg every day in patients with hypercholesterolemia.
    Rindone JP; Hiller D; Arriola G
    Pharmacotherapy; 1998; 18(4):836-9. PubMed ID: 9692657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency.
    Samuelsson O; Attman PO; Knight-Gibson C; Mulec H; Weiss L; Alaupovic P
    Am J Kidney Dis; 2002 Jan; 39(1):67-75. PubMed ID: 11774104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and pharmacology of fluvastatin.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1996 Jan; 77A():11-5. PubMed ID: 8729584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and pharmacology of fluvastatin.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):11-5. PubMed ID: 19489169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
    Leitersdorf E; Eisenberg S; Eliav O; Friedlander Y; Berkman N; Dann EJ; Landsberger D; Sehayek E; Meiner V; Wurm M
    Circulation; 1993 Apr; 87(4 Suppl):III35-44. PubMed ID: 8462179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate.
    Greten H; Beil FU; Schneider J; Weisweiler P; Armstrong VW; Keller C; Klör HU; von Hodenberg E; Weidinger G; Eskötter H
    Am J Med; 1994 Jun; 96(6A):55S-63S. PubMed ID: 8017468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
    Park S; Kang HJ; Rim SJ; Ha JW; Oh BH; Chung N; Cho SY
    Clin Ther; 2005 Jul; 27(7):1074-82. PubMed ID: 16154486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.